Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zyvox Phase IV Studies May Support Penicillin-Resistant Indications

Executive Summary

Pharmacia will continue to seek additional indications for Zyvox (linezolid) in the treatment of antibiotic-resistant infections.
Advertisement

Related Content

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t
FDA Wants Promotional “Targets” From Sponsors Throughout Drug Development
FDA Wants Promotional “Targets” From Sponsors Throughout Drug Development
Synercid, Zyvox Drug Pricing Discourages Use, IDSA Rep Says
Synercid, Zyvox Drug Pricing Discourages Use, IDSA Rep Says
Pharmacia Zyvox
Pharmacia Zyvox
Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.
Pathogen-Resistant Antibiotic Indications Questioned By FDA Cmte.
Zyvox Dose Adjustments Not Necessary For Renally Impaired Patients - P&U
Advertisement
UsernamePublicRestriction

Register

PS035948

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel